Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07551635 · ClinicalTrials.gov registry record · Phase 2
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Not yet
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT07551635: Clinical Trial Phase 2 study, sponsored by Dana-Farber Cancer Institute.
NCT07551635 is a Phase 2 study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07551635, a Phase 2 study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a single-arm, phase II clinical trial evaluating the efficacy and safety of FHD-286, a SMARCA4/2 inhibitor, in participants with POU2F3-expressing small cell lung cancer who have received at least one prior line of platinum-based therapy. All participants will receive FHD-286 orally once daily in 21-day cycles. The primary objective is to assess the objective response rate of FHD-286 in this population. The names of the study drug involved in this study is: • FHD-286 (a small-molecule SMARCA4/2 ATPase (BRG1 and BRM) inhibitor targeting the SWI/SNF chromatin remodeling complex (also known as the BAF complex)
Primary Outcome
ORR is the percentage of participants achieving complete or partial response on treatment based on RECIST v1.1 criteria (Eisenhauer et al Eur J Ca 45:228-247, 2009).
Interventions
- DRUG FHD-286
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-09-04 |
| Est. Completion | 2029-01-31 |
| Phase | Phase 2 |
What is known before NCT07551635 opens enrollment
NCT07551635 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which FHD-286 is the first listed.
NCT07551635 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07551635 about?
NCT07551635 is a clinical study titled "SMARCA4/2 Inhibitor for POU2F3-Positive SCLC". This is a single-arm, phase II clinical trial evaluating the efficacy and safety of FHD-286, a SMARCA4/2 inhibitor, in participants with POU2F3-expressing small cell lung cancer who have received at least one prior line of platinum-based therapy. All participants will receive FHD-286 orally once dai...
What is the current status of trial NCT07551635?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-09-04. Estimated completion is 2029-01-31.
What interventions are being tested in trial NCT07551635?
The interventions under investigation include: FHD-286 (DRUG).
Who is sponsoring clinical trial NCT07551635?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07551635's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI